2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Raloxifene hydrochloride (RAL), one of second generation of selective estrogen receptor modulators (SERMs), is usually used in preventing osteoporosis and breast cancer. The present study evaluated whether Raloxifene might sensitize multidrug resistant (MDR) breast cancers to chemotherapies, especially in estrogen receptor negative (ER−) breast cancer. The results showed that RAL could significantly sensitize ER- MDR breast tumors to paclitaxel both in vitro and in vivo. Combination of Raloxifene could significantly enhance paclitaxel-induced cell apoptosis, G2-M arrest as well as inhibition of cell proliferation in MDR tumors. Further studies showed that the combined treatment did not alter P-glycoprotein expression but increased P-gp ATPase activity. These results suggested that raloxifene might be a valuable chemosensitizer agent for breast cancer therapy.

          Related collections

          Author and article information

          Journal
          Cancer Biol Ther
          Cancer Biol. Ther
          KCBT
          Cancer Biology & Therapy
          Taylor & Francis
          1538-4047
          1555-8576
          December 2015
          3 November 2015
          : 16
          : 12
          : 1794-1801
          Affiliations
          [1 ] Program of Innovative Cancer Therapeutics; Department of Surgery
          [2 ] Clinical Research Center; First Affiliated Hospital of Zhejiang University School of Medicine ; Hangzhou, China
          [3 ] Department of Biological Sciences; National University of Singapore ; Singapore
          [4 ] Department of Pathology and Laboratory Medicine; Medical University of South Carolina ; SC, USA
          Author notes

          These authors contributed equally to this paper.

          [* ]Correspondence to: Weimin Fan; Email: fanw@ 123456zju.edu.cn
          Article
          PMC4847829 PMC4847829 4847829 1095409
          10.1080/15384047.2015.1095409
          4847829
          26529585
          e023f5c9-c8ca-42e7-8fd2-8d9b1347cd95
          © 2015 Taylor & Francis Group, LLC
          History
          : 26 June 2015
          : 12 September 2015
          : 12 September 2015
          Page count
          Figures: 6, Tables: 0, References: 44, Pages: 8
          Categories
          Research Paper

          multidrug resistance,breast cancer,paclitaxel,raloxifene

          Comments

          Comment on this article